Drug intelligence / Profile preview

HDM2025

Development stage: Preclinical
Lead developer: Huadong Medicine
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

HDM2025 is a preclinical-stage pan-KRAS protein degrader developed by Huadong Medicine for the treatment of various cancers. It is designed to target and degrade multiple oncogenic variants of the KRAS protein, a common driver in many solid tumors. By utilizing a protein degradation mechanism (likely a PROTAC), HDM2025 aims to overcome the limitations of traditional KRAS inhibitors that often target specific mutations like G12C. The compound has shown potent and selective pan-KRAS targeting capabilities in preclinical studies and was featured at the 2025 ASCO conference.

Other names: pan-KRAS protein degrader

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on HDM2025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDM2025.

Explore the full profile